Wednesday, January 15, 2025
News

Liraglutide increases insulin sensitivity without causing weight loss: Study

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Los Angeles | January 5, 2024 3:50:26 PM IST
Research published in 'Diabetes' showed that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a kind of medicine used to treat type 2 diabetes and obesity, can lead to a quick increase in insulin sensitivity.

Insulin sensitivity refers to how sensitive cells are to insulin, a hormone that regulates blood glucose levels. Increased insulin sensitivity indicates that insulin can reduce blood glucose levels more efficiently.

Type 2 diabetes is characterised by decreased insulin sensitivity or insulin resistance. Improved insulin sensitivity can therefore lower the chance of developing Type 2 diabetes or enhance therapy.

GLP-1R agonists are drugs that impact metabolism by increasing insulin secretion and thereby lowering blood sugar levels.

Dipeptidyl peptidase 4 (DPP-4) inhibitors prevent the breakdown of the body's own endogenous GLP-1, as well as other peptide hormones such as glucose-dependent insulinotropic peptide (GIP).

"We know that GLP-1R agonists promote weight loss, but we were surprised to find that the GLP-1R agonist liraglutide also has rapid effects on insulin sensitivity, independent from weight loss," said Mona Mashayekhi, MD, PhD, assistant professor of medicine in the Division of Diabetes, Endocrinology and Metabolism.

"This effect requires activation of the GLP-1 receptor, but increasing the body's own endogenous GLP-1 through the use of the DPP4 inhibitor sitagliptin does not achieve similar effects."

"Our research suggests that liraglutide, and presumably other GLP-1R agonists, are having important metabolic effects in a way that's different from increasing endogenous GLP-1 levels, even though they're using the same receptor. Future research will focus on potential mechanisms of how GLP-1R agonists are improving insulin sensitivity independent of weight loss."

Eighty-eight individuals with obesity and pre-diabetes were randomized for 14 weeks to receive the GLP-1R agonist liraglutide, the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin, or weight loss without drug using a low-calorie diet.

To further investigate the GLP-1R-dependent effects of the treatments, the GLP-1R antagonist exendin and a placebo were given in a two-by-two crossover study during mixed meal tests. Crossover studies allow the response of a subject to treatment A to be compared with the same subject's response to treatment B.

Liraglutide was shown to rapidly improve insulin sensitivity as well as decrease blood glucose within two weeks of beginning treatment and before any weight loss.

"GLP-1R agonists are an exciting class of medications, given their strong glucose-lowering effects combined with tremendous weight-loss benefits, and they have transformed how we manage diabetes and obesity in the clinic," Mashayekhi said.

"Since the number of medications in this class is rapidly expanding, a deeper understanding of the mechanisms of benefit is crucial so we can design the right drugs for the desired effects in the right patients." (ANI)

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE HEALTH NEWS
Bioengineers found breakthrough in build...
Fibre in diet may boost the body against...
Research discovers new skeletal tissue w...
Revolutionizing Hip Replacement Surgery:...
Mrs. Neerja Birla Initiative Mpower Stre...
Gujarat health minister issues advisory ...
More...
 
INDIA WORLD ASIA
UP CM Yogi, SP Chief Akhilesh Yadav exte...
'Upar wala bachayega,' says Arvind Kejri...
Uttarakhand: CM Dhami unveils BJP's 'San...
Devotees continue to arrive at Triveni S...
Mahamandaleshwar Swami Rupendra Prakash ...
'Deepest gratitude and homage to brave w...
More...    
 
 Top Stories
"Australia was lucky......": Ashwin... 
Luv Ranjan's Marathi film 'Devmanus... 
TikTok executive alleges forced oat... 
SC grants interim protection from a... 
Sachin Pilot questions RSS chief's ... 
Union Minister Scindia sends letter... 
US-India tax forum proposes bold re... 
Djokovic battles past another debut...